Applications of the biomakerdetection technology guiding neoadjuvant therapy for advanced esophageal cancer

doi:10.3760/cma.j.issn.1673-422X.2015.12.011

Abstract

Abstract: At present, the technology to predict the response to neoadjuvant therapy with biomakers has been widely used in clinical practice. The approaches of biomarkers detection are various, including immunohistochemistry, detection of serum biomarkers conventional blood tests, gene expression profile analysis, single nucleotide polymorphisms, miRNAs, proteomics analysis. With the development of biotechnology, the technology of biomarkers detection is expected to become effective means in assessment of adjuvant therapy, risk, prognosis and individualization in esophageal cancer treatment.

Key words: Esophageal neoplasms, Biological makers, Neoadjuvant therapy

Li Chen, Cheng Yufeng. Applications of the biomakerdetection technology guiding neoadjuvant therapy for advanced esophageal cancer[J]. Journal of International Oncology, 2015, 42(12): 924-927.

References

［1］ Bollschweiler E, Hlscher AH, Metzger R. Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer［J］. Future Oncol, 2010, 6(1): 25-35. ［2］ Nguyen NP, Krafft SP, VinhHung V, et al. Feasibility of tomotherapy to reduce normal lung and cardiac toxicity for distal esophageal cancer compared to threedimensional radiotherapy［J］. Radiother Oncol, 2011, 101(3): 438-442. ［3］ Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival［J］. J Clin Oncol, 2005, 23(19): 4330-4337. ［4］吕雅蕾，刘巍，左静，等． ERCC1、ERCC2与食管癌临床病理特征和预后关系的研究［J］．临床肿瘤学杂志， 2010， 7（7）： 600-604．［5］ Yamamoto Y, Yamai H, Seike J, et al. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin［J］. Ann Surg Oncol, 2012, 19(3): 757-765. ［6］ Vallbhmer D, Lenz HJ. Predictive and prognostic molecular markers in outcome of esophageal cancer［J］. Dis Esophagus, 2006, 19(6): 425-432. ［7］ Yasunaga M, Tabira Y, Nakano K, et al. Accelerated growth signals and low tumorinfiltrating lymphocyte levels predict poor outcome in T4 esophageal squamous cell carcinoma［J］. Ann Thorac Surg, 2000, 70(5): 1634-1640. ［8］郑成义，王朝阳，闻吉军，等．食管鳞癌中NFκB、p53的表达及其与新辅助化疗敏感性的关系［J］．现代肿瘤医学， 2009， 12（12）： 2328-2330．［9］ Brabender J, Metzger R, Vallbhmer D, et al. Roles of thymidylate synthase and dihydropyrimidine dehydrogenase expression in blood as predictors of response to multimodal therapy in esophageal cancer［J］. Surgery, 2012, 151(2): 306-312. ［10］ Makuuchi Y, Honda K, Osaka Y, et al. Soluble interleukin6 receptor is a serum biomarker for the response of esophageal carcinoma to neoadjuvant chemoradiotherapy［J］. Cancer Sci, 2013, 104(8): 1045-1051. ［11］ Grimminger P, Vallbhmer D, Hoffmann A, et al. Quantitative analysis of survivin RNA expression in blood as a noninvasive predictor of response to neoadjuvant radiochemotherapy in esophageal cancer［J］. J Surg Oncol, 2009, 100(6): 447-451. ［12］李杰．食管癌放疗前后多种生物标志物联合检测的临床意义［J］．肿瘤研究与临床， 2009， 12（21）： 837-839．［13］ Noble F, Hopkins J, Curtis N, et al. The role of systemic inflammatory and nutritional bloodborne markers in predicting response to neoadjuvant chemotherapy and survival in oesophagogastric cancer［J］. Med Oncol, 2013, 30(3): 596. ［14］ Luthra R, Wu TT, Luthra MG, et al. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation［J］. J Clin Oncol, 2006, 24(2): 259-267. ［15］ Duong C, Greenawalt DM, Kowalczyk A, et al. Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer［J］. Ann Surg Oncol, 2007, 14(12): 3602-3609. ［16］ Maher SG, Gillham CM, Duggan SP, et al. Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer［J］. Ann Surg, 2009, 250(5): 729-737. ［17］ Metzger R, Heukamp L, Drebber U, et al. CUL2 and STK11 as novel responsepredictive genes for neoadjuvant radiochemotherapy in esophageal cancer［J］. Pharmacogenomics, 2010, 11(8): 1105-1113. ［18］ Motoori M, Takemasa I, Yamasaki M, et al. Prediction of the response to chemotherapy in advanced esophageal cancer by gene expression profiling of biopsy samples［J］. Int J Oncol, 2010, 37(5): 1113-1120. ［19］ Glinsky GV. Integration of HapMapbased SNP pattern analysis and gene expression profiling reveals common SNP profiles for cancer therapy outcome predictor genes［J］. Cell Cycle, 2006, 5(22): 2613-2625. ［20］ Metzger R, WarneckeEberz U, Alakus H, et al. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis［J］. J Gastrointest Surg, 2012, 16(1): 26-34; discussion 34. ［21］ Bradbury PA, Kulke MH, Heist RS, et al. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes［J］. Pharmacogenet Genomics, 2009, 19(8): 613-625. ［22］ Bhatti I, Lee A, Lund J, et al. Small RNA: a large contributor to carcinogenesis?［J］. J Gastrointest Surg, 2009, 13(7): 1379-1388. ［23］ Maru DM, Singh RR, Hannah C, et al. MicroRNA196a is a potential marker of progression during Barrett′s metaplasiadysplasiainvasive adenocarcinoma sequence in esophagus［J］. Am J Pathol, 2009, 174(5): 1940-1948. ［24］ Ogawa R, Ishiguro H, Kuwabara Y, et al. Expression profiling of microRNAs in human esophageal squamous cell carcinoma using RTPCR［J］. Med Mol Morphol, 2009, 42(2): 102-109. ［25］ Odenthal M, Bollschweiler E, Grimminger PP, et al. MicroRNA profiling in locally advanced esophageal cancer indicates a high potential of miR192 in prediction of multimodality therapy response［J］. Int J Cancer, 2013, 133(10): 2454-2463. ［26］ Ko MA, Zehong G, Virtanen C, et al. MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy［J］. Ann Thorac Surg, 2012, 94(4): 1094-1102; discussion 1102-1103. ［27］ Ota Y, Takagi Y, Osaka Y, et al. Usefulness of serum protein profiling for prediction of preoperative chemoradiosensitivity of esophageal cancer［J］. Oncol Rep, 2007, 18(3): 653-657. ［28］ Maher SG, Mcdowell DT, Collins BC, et al. Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation［J］. Ann Surg, 2011, 254(5): 809-816; discussion 816-817.

[1]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[2]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[3]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[4]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[5]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[6]	Shandong Medical Association Multidisciplinary Joint Committee on Lung Cancer. Shandong Provincial Medical Association multidisciplinary standardized diagnosis and treatment guidelines for esophageal carcinoma （2023 Edition） [J]. Journal of International Oncology, 2023, 50(7): 385-397.
[7]	Xu Fang, Zhu Wentian. Progress in adjuvant therapy of hepatocellular carcinoma complicated with microvascular invasion [J]. Journal of International Oncology, 2023, 50(5): 304-309.
[8]	Ji Shiyu, Zhang Mingxin, Xie Huahong, Bai Yuan, Wang Tong. Observation on the efficacy of different stents in the treatment of patients with advanced esophageal cancer [J]. Journal of International Oncology, 2023, 50(2): 76-81.
[9]	Gong Heyi, Yi Yan, Zhang Jian, Li Baosheng. Management strategies for locally advanced operable esophageal carcinoma achieving clinical complete response after neoadjuvant chemoradiotherapy [J]. Journal of International Oncology, 2023, 50(12): 745-750.
[10]	Wu Puyuan, Qi Liang, Wang Tao, Shi Minke, Sun Yuwei, Wang Lifeng, Liu Baorui, Yan Jing, Ren Wei. Efficacy of postoperative radiotherapy based on modified clinical target volume according to high-frequency recurrence regions in patients with esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2022, 49(8): 464-472.
[11]	Xia Lingling, Chen Yongshun, Li Bin, Ning Tingting, Zhang Caiyutian. Comparison of safety and efficacy between chemoradiotherapy and chemotherapy after R0 resection in pN₊ esophageal squamous cell carcinoma patients [J]. Journal of International Oncology, 2022, 49(6): 334-339.
[12]	Cai Gangxiang, Li Jing, Xu Bin. Advances in neoadjuvant immunotherapy for lung cancer [J]. Journal of International Oncology, 2022, 49(6): 366-370.
[13]	Ye Qian, Ling Zhi, Liu Shenxiang, Lu Guotao, Yin Xudong. Effects of sarcopenia on the clinical efficacy and prognosis of radical radiotherapy in elderly patients with esophageal cancer [J]. Journal of International Oncology, 2022, 49(4): 199-205.
[14]	Zhou Jianfeng, Wang Tiejun. Targeted therapy and immunotherapy of esophageal cancer [J]. Journal of International Oncology, 2022, 49(4): 237-242.
[15]	Liu Jia, Ge Xiaolin, Di Xiaoke, Shi Yujing, Zeng Yuting. Efficacy analysis of Xiyanping injection on prevention of radioactive esophagitis [J]. Journal of International Oncology, 2022, 49(3): 146-150.